Page 11 - Vaccine

Govt panel may decide on Covovax as heterologous booster dose for adults

An expert panel of the central drugs regulatory authority is likely to take a decision on Wednesday on granting market authorisation to SII's COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said. The Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) is scheduled to meet on January 11. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had written a letter to the the Drugs Controller General of India (DCGI) recently for the approval to Covovax as a heterologous booster dose for adults in view of the escalating pandemic situation in some countries, an official source told. The DCGI had approved Covovax for restricted use in emergency situations for adults on December 28, 2021, for those in the 12-17 age group on March 9, 2022, and also in children aged 7- 11 years on June 28, 2022, subject to certai

Clinical trials of new BCG vaccine for TB to start soon: Former CSIR chief

Clinical trials of a new BCG vaccine for tuberculosis will soon start in India, former director-general of the Council of Scientific & Industrial Research (CSIR) Dr Shekhar Mande said on Friday. He was speaking at the ongoing Indian Science Congress here. Earlier in the day, Dr Mande gave a presentation on Biophysical Methods in Tuberculosis Research' and spoke about how technology has helped doctors and researchers understand TB better, paving ways to combat the infectious disease. The CSIR is working towards rapid diagnosis, vaccination and treatment to eliminate the bacterial disease from India by 2025 as envisioned by the government, he said, speaking to reporters later. We are mainly focussing on new medicines and drugs for tuberculosis. We are doing background work and setting targets on research for prevention of tuberculosis, he said The National Institute of Tuberculosis Research, Chennai, will start clinical trials of the new BCG vaccine for TB, he said. Bacillus ...

All you need to know about world's first nasal vaccine for covid

The government has approved Bharat Biotech's intranasal Covid-19 vaccine, iNCOVACC (BBV154), as a booster dose for those above 18 years of age. How does this needle-free vaccine work and how different is it from the existing ones? To get the answers, Business Standard spoke to Dr Gagandeep Kang, virologist and professor at the Christian Medical College, Vellore. Watch the video for more

India's nasal vaccine not for those who have taken booster: NTAGI chairman

The Indian nasal vaccine cannot be given to those who have allready taken a precaution or booster dose, the head of the country's vaccine task force said

We aim to be one of India's top CDMO, API players: Advent's Shweta Jalan

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

Covid-19: Bharat Biotech's nasal vaccine gets govt nod as booster shot

The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries

As Covid-19 cases fall, Indians drag feet to get their booster shots

Less than 30,000 booster doses daily in December, vaccine coverage flat for two months

DCGI approves Biological E's 14-valent pneumococcal conjugate vaccine

PCV14 may be administered to infants 6, 10 and 14 weeks of age in 3 doses

Takeda's dengue vaccine QDENGA gets EU's authorisation use approval

The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.

Meta bars employees from discussing abortion, vaccine efficacy at work

Meta (formerly Facebook) has reportedly told its employees not to discuss sensitive issues like abortion, gun control, pending legislation and vaccine efficacy at workplace

Lessons from Covid: Pharma firms turn attention to adult vaccination

Vaccine companies have warmed up to the idea of adult vaccines for other diseases such as pneumonia, flu and shingles as well

4.8 mn children to get Japanese Encephalitis vaccine from Dec 5: K'taka Min

A special vaccination drive to inoculate an estimated 48 lakh children aged between 1-15 against Japanese Encephalitis (JE) will be held in Karnataka from December 5 for a period of three weeks, State Health Minister K Sudhakar said on Sunday. Encephalitis is the inflammation of the brain caused by either infection or an allergic reaction. "JE is one of the most common causes of Encephalitis in India and a total of 68,000 cases are reported every year. Among these, the death rate is around 20 to 30 per cent. Among those who are cured, 30 to 50 per cent of people end up with sensory and motor weakness, and other permanent physical and mental disabilities," Sudhakar said. "In the first week now (December), vaccinations will primarily be focused on Private and Government schools, following this, in the next two weeks, we will be focusing on vaccination drives in health institutions, Anganwadi centers and among communities," he said. Union Health Ministry will be supplying the Jenvac .

With the flu season here, should you ask for an influenza vaccine?

Demand for flu vaccine weak in India; US facing worst season in a decade

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Bharat Biotech gets nasal vaccine nod for use as mix-match booster

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us

Flu vaccine that can protect against all 20 known influenza virus developed

The "multivalent" vaccine, described in a paper published in Science, uses the same messenger ribonucleic acid (mRNA) technology employed in the Pfizer and Moderna SARS-CoV-2 vaccines

Mumbai measles outbreak, missed vaccination: Here's all you need to know

According to US Centers for Disease Control and Prevention (CDC) data, currently India has the highest number of cases in the world at 9,489

Removing vaccination mandate for incoming tourists correct move: Experts

With over 90% of population being vaccinated, it is okay at a policy level to relax the mandatory vaccination norm for entering India, they say

BioNTech Q3 earnings drop but forecast for vaccine revenue grows

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, reported that its earnings in the third quarter were close to half what they were a year earlier, but the German pharmaceutical company still raised its expectations for vaccine revenue after rolling out updated shots targeting omicron strains. The company said Monday that it made net profit of 1.8 billion euros (USD 1.8 billion) off revenue of 3.5 billion euros (USD 3.5 billion) in the three months to September, a drop from profit of 3.2 billion euros and revenue of 6.1 billion euros in the same period a year ago. BioNTech said the course of the pandemic remains dynamic and led to fluctuations" in earnings. Profit and revenue were largely flat in the first nine months of the year. Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range," said Jens Holstein, CFO of BioNTech. We started shipments of o

Moderna misses Q3 expectations, net income dips 69%; defers vaccine sales

Sliding COVID-19 vaccine sales and rising expenses for Moderna combined to produce a third quarter that missed Wall Street expectations. The vaccine developer also said on Thursday that it was dialling back its revenue expectations from advance purchase agreements for this year, as some sales will be deferred to 2023. Moderna also said on Thursday that between USD 2 billion and USD 3 billion in vaccine sales will be deferred to next year, and the company now expects between USD 18 billion and USD 19 billion in revenue from advance purchase agreements this year. That's down from the approximately USD 21 billion it forecast in August. Company shares tumbled in early-morning trading. The vaccine developer said its Spikevax vaccine brought in USD 3.12 billion in sales during the quarter, a 35 per cent drop compared to last year. Moderna also scaled back expectations for COVID-19 vaccine deliveries in last year's third quarter due to supply issues. CEO Stephane Bancel said then that t